The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer